These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19242023)

  • 1. Recent landmark trials in cardiology 2008.
    Jain P; Bhandari S
    Indian Heart J; 2008; 60(4):372-6. PubMed ID: 19242023
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent advances in cardiology.
    Menown IA; Shand JA
    Future Cardiol; 2010 Jan; 6(1):11-7. PubMed ID: 20014984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The year in interventional cardiology.
    Dixon SR; Grines CL; O'Neill WW
    J Am Coll Cardiol; 2009 Jun; 53(22):2080-97. PubMed ID: 19477360
    [No Abstract]   [Full Text] [Related]  

  • 4. [Summary of the clinical studies reported in the scientific session of the American Heart Association 2005 (Dallas, Texas, USA, 13-16 November 2005)].
    Bermejo J; Segovia J; Alfonso F
    Rev Esp Cardiol; 2006 Feb; 59(2):143-53. PubMed ID: 16540036
    [No Abstract]   [Full Text] [Related]  

  • 5. The year in interventional cardiology.
    O'Neill WW; Dixon SR; Grines CL
    J Am Coll Cardiol; 2005 Apr; 45(7):1117-34. PubMed ID: 15808773
    [No Abstract]   [Full Text] [Related]  

  • 6. Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
    Spinler SA
    Am J Manag Care; 2009 Mar; 15(2 Suppl):S42-7. PubMed ID: 19355808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007.
    Daemen J; Simoons ML; Wijns W; Bagust A; Bos G; Bowen JM; Braunwald E; Camenzind E; Chevaliers B; DiMario C; Fajadeto J; Gitt A; Guagliumi G; Hillege HL; James S; Jüni P; Kastrati A; Kloth S; Kristensen SD; Krucoff M; Legrand V; Pfisterer M; Rothman M; Serruys PW; Silber S; Steg PG; Tariah I; Wallentin L; Windecker SW; Aimonetti A; Allocco D; Berenger M; Boam A; Calle JP; Campo G; Carlier S; de Schepper J; Di Bisceglie G; Dobbels H; Farb A; Ghislain JC; Hellbardt S; ten Hoedt R; Isaia C; de Jong P; Lekehal M; LeNarz L; Mhullain FN; Nagai H; Patteet A; Paunovic D; Potgieter A; Purdy I; Raveau-Landon C; Ternstrom S; Van Wuytswinkel J; Waliszewski M;
    EuroIntervention; 2009 Jan; 4(4):427-36. PubMed ID: 19284063
    [No Abstract]   [Full Text] [Related]  

  • 8. [Polyphepan (lignin) as an hypocholesteremic agent].
    Frolkis AV; Abramzon MA; Kislova GD; Levanova VP
    Klin Med (Mosk); 1987 Jul; 65(7):48-52. PubMed ID: 3312799
    [No Abstract]   [Full Text] [Related]  

  • 9. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing technological explosion in the medical management of coronary artery disease. Cardiovascular administrators are key internal consultants in planning for drug-eluting stent technology.
    DeCerce J; Chumer K
    J Cardiovasc Manag; 2002; 13(3):13-6. PubMed ID: 12048868
    [No Abstract]   [Full Text] [Related]  

  • 11. LDL-Cholesterol is the King.
    Goumas GS
    Angiology; 2009; 60(3):387-8. PubMed ID: 19497926
    [No Abstract]   [Full Text] [Related]  

  • 12. Pioneers in cardiology.
    Serruys P
    Circulation; 2006 Jan; 113(3):f11-2. PubMed ID: 16435421
    [No Abstract]   [Full Text] [Related]  

  • 13. [Echo of the 2005 ACC* (2). The war of stents has started].
    Schaerlig E
    Rev Med Suisse; 2005 May; 1(20):1378, 1381. PubMed ID: 15991632
    [No Abstract]   [Full Text] [Related]  

  • 14. Xience V everolimus-eluting coronary stent.
    Kukreja N; Onuma Y; Serruys PW
    Expert Rev Med Devices; 2009 May; 6(3):219-29. PubMed ID: 19419279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left main coronary artery stenting: crossing the Rubicon.
    Alfonso F
    J Am Coll Cardiol; 2009 May; 53(19):1769-72. PubMed ID: 19422983
    [No Abstract]   [Full Text] [Related]  

  • 16. [Left main coronary stenting is safe and effective and is a valuable alternative to coronary artery bypass graft surgery].
    Sheiban I; Zoccai GB; Moretti C
    G Ital Cardiol (Rome); 2009 Feb; 10(2):113-7; discussion 117. PubMed ID: 19348149
    [No Abstract]   [Full Text] [Related]  

  • 17. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease.
    Nikolsky E; Lansky AJ; Sudhir K; Doostzadeh J; Cutlip DE; Piana R; Su X; White R; Simonton CA; Stone GW
    Am Heart J; 2009 Oct; 158(4):520-526.e2. PubMed ID: 19781409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-eluting stents for the treatment of coronary artery disease: NICE technology appraisal guidance.
    Messori A; Trippoli S
    Heart; 2009 May; 95(10):847. PubMed ID: 19401286
    [No Abstract]   [Full Text] [Related]  

  • 19. Myocardial Bridge in association with fixed atherosclerotic lesions treated with drug-eluting stents: a follow-up report with quantitative coronary analysis.
    Arora P; Bhatia V; Parida AK; Kaul U
    Indian Heart J; 2008; 60(6):594-6. PubMed ID: 19276504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When can noninferior be superior? The multidimensional nature of clinical decision-making calls for innovative approaches to clinical trials.
    Ohman EM; Califf RM
    J Am Coll Cardiol; 2010 Feb; 55(6):555-7. PubMed ID: 20152560
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.